The present invention relates to a novel sustained-release oral dosage form for treating interstitial cystitis comprising 300 mg of pentosan polysulfate sodium, at least one retardant and pharmaceutically acceptable excipients, wherein the dosage form provides drug release for a prolonged period of time after administration. It also relates to the use of the novel sustained-release oral dosage form for treating interstitial cystitis.